Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease

  • Authors: Judith S. Currier, MD, MSc; Risa Hoffman, MD, MPH (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/10/18 (What's New)

Summary

  • HIV-infected patients should be assessed for typical CVD risk factors, hyperlipidemia, and diabetes at entry into care
    • Fasting lipid profile and screening for diabetes should be performed every 6-12 months in all patients, as well as with screening for dyslipidemia and diabetes before ART initiation, and 1-3 months after ART initiation or switches[Aberg 2014]
  • Frequent blood pressure monitoring is advised

Action required

Keywords: Cardiovascular Disease, Treatment Complications

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.